Spero therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., dec. 22, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that on december 19, 2022, the compensation committee of spero's board of directors approved a grant of 155,000 restricted stock unit awards (rsus) to one new employee under the spero therapeutics, inc. 2019 inducement equity incentive plan, as amended, or the 2019 inducement plan. the rsus are being granted as inducements material to the new employee becoming an employee of spero in accordance with nasdaq listing rule5635(c)(4).
SPRO Ratings Summary
SPRO Quant Ranking